126 related articles for article (PubMed ID: 35550167)
1. Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma.
Wei T; Lin R; Fu X; Lu Y; Zhang W; Li Z; Zhang J; Wang H
Pharmacol Res; 2022 Jun; 180():106244. PubMed ID: 35550167
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Liu J; Liu Y; Meng L; Liu K; Ji B
Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
[TBL] [Abstract][Full Text] [Related]
3. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
Houessinon A; François C; Sauzay C; Louandre C; Mongelard G; Godin C; Bodeau S; Takahashi S; Saidak Z; Gutierrez L; Régimbeau JM; Barget N; Barbare JC; Ganne N; Chauffert B; Coriat R; Galmiche A
Mol Cancer; 2016 May; 15(1):38. PubMed ID: 27184800
[TBL] [Abstract][Full Text] [Related]
4. Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma.
Pang L; Xu L; Yuan C; Li X; Zhang X; Wang W; Guo X; Ouyang Y; Qiao L; Wang Z; Liu K
Mol Carcinog; 2019 Nov; 58(11):2118-2126. PubMed ID: 31465134
[TBL] [Abstract][Full Text] [Related]
5. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
[No Abstract] [Full Text] [Related]
6. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
7. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
8. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib.
Zhang Y; Feng J; Mi Y; Fan W; Qin R; Mei Y; Jin G; Mao J; Zhang H
Drug Metab Dispos; 2024 May; 52(6):555-564. PubMed ID: 38565301
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
11. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
13. ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence.
Chen J; Li H; Zhang B; Xiong Z; Jin Z; Chen J; Zheng Y; Zhu X; Zhang S
Liver Int; 2022 Nov; 42(11):2562-2576. PubMed ID: 36017822
[TBL] [Abstract][Full Text] [Related]
14. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
[TBL] [Abstract][Full Text] [Related]
15. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
16. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
17. 3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma.
Hua KT; Liu YF; Hsu CL; Cheng TY; Yang CY; Chang JS; Lee WJ; Hsiao M; Juan HF; Chien MH; Yang SF
Sci Rep; 2017 Jun; 7(1):4466. PubMed ID: 28667334
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
19. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
[TBL] [Abstract][Full Text] [Related]
20. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
Xiang DM; Sun W; Zhou T; Zhang C; Cheng Z; Li SC; Jiang W; Wang R; Fu G; Cui X; Hou G; Jin GZ; Li H; Hou C; Liu H; Wang H; Ding J
Gut; 2019 Oct; 68(10):1858-1871. PubMed ID: 31118247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
